# A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

> **NCT01965613** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 10 (actual)

## Conditions studied

- Pyoderma Gangrenosum

## Interventions

- **BIOLOGICAL:** Xilonix

## Key facts

- **NCT ID:** NCT01965613
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-31
- **Primary completion:** 2016-12-31
- **Final completion:** 2016-12-31
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01965613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01965613, "A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01965613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*